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Abstract
Background: Photoreceptor death leads to vision impairment in several retinal degenerative disorders. Therapies
protecting photoreceptor from degeneration remain to be developed. Anti-inflammation, anti-oxidative stress, and
neuroprotective effects of celastrol have been demonstrated in a variety of disease models. The current study
aimed to investigate the photoreceptor protective effect of celastrol.
Methods: Bright light-induced retinal degeneration in BALB/c mice was used, and morphological, functional, and
molecular changes of retina were evaluated in the absence and presence of celastrol treatment.
Results: Significant morphological and functional protection was observed as a result of celastrol treatment in
bright light-exposed BALB/c mice. Celastrol treatment resulted in suppression of cell death in photoreceptor cells,
alleviation of oxidative stress in the retinal pigment epithelium and photoreceptors, downregulation of retinal
expression of proinflammatory genes, and suppression of microglia activation and gliosis in the retina. Additionally,
leukostasis was found to be induced in the retinal vasculature in light-exposed BALB/c mice, which was significantly
attenuated by celastrol treatment. In vitro, celastrol attenuated all-trans-retinal-induced oxidative stress in cultured
APRE19 cells. Moreover, celastrol treatment significantly suppressed lipopolysaccharides-stimulated expression of
proinflammatory genes in both APRE19 and RAW264.7 cells.
Conclusions: The results demonstrated for the first time that celastrol prevents against light-induced retinal
degeneration through inhibition of retinal oxidative stress and inflammation.
Background
Photoreceptor cell death plays important role in the
pathogenesis of vision impairment in several retinal
degenerative disorders, for instance, retinitis pigmentosa
(RP), Stargardt disease, and age-related macular degener-
ation (AMD) [1, 2]. Light damage to the retina is caus-
ally associated with human retinal degeneration [3].
Light-induced retinal degeneration in rodents is primar-
ily characterized by apoptotic photoreceptor cell death,
mimicking clinical pathologies of human retinal disor-
ders [4]. Thus, animal model of light-induced retinal de-
generation is widely adopted to investigate retinal
protective therapies against the loss of photoreceptors.
To date, no effective photoreceptor protective therapies
are clinically available yet, and therapeutic development
targeting photoreceptor cell death is required for opti-
mal vision preservation.
Oxidative stress is causally associated with cell death
through multiple mechanisms and is regarded as one of
the central players in the pathogenesis of various retinal
degenerative disorders [5–8]. Accumulated evidence has
also supported an important role of inflammation in the
pathogenesis of retinal degenerative disorders [9–11].
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Celastrol is a naturally occurring quinone methide triter-
pene present in Celastraceae family herbs that have a
long history of usage in traditional Chinese medicine to
treat chronic inflammation and autoimmune diseases in
patients [12]. In addition to the effects on inflammation,
autoimmune disorders, cancer, and obesity [13–16], the
neuroprotective effect of celastrol in part implicating the
mechanism of anti-oxidative stress has also been re-
ported in a number of models [17–20]. A recent study
has also reported that celastrol protects ganglion cells
(GC) from optic nerve crush-induced damage through
inhibiting retinal expression of TNF-α [21]. However,
whether celastrol could protect photoreceptors from de-
generation remains to be addressed.
In the current study, the effect of celastrol on light-
induced retinal degeneration was evaluated in BALB/c
mice. The results revealed significant morphological and
functional protection of celastrol against bright light-
induced retinal damage. The results also demonstrated
that bright light caused prominent oxidative stress in
retinal pigment epithelium (RPE), enhanced retinal ex-
pression of proinflammatory genes, microglial activa-
tion, and retinal gliosis and leukostasis in retinal




Four- to 5-week-old female BALB/c mice were pur-
chased from Shanghai Laboratory Animal Research Cen-
ter. Mice were housed in a 12/12-h light-dark cycle
room with temperature of 25 ± 2 °C. For bright light
exposure experiments, mice were dark-adapted for 24 h
prior to white light exposure (compact fluorescence
lamp, 45 W, Chaoya Lighting, Shanghai, China) at
5000 lx for 2 h and 10,000 lx for 2 h or 30 min. All the
animal handling procedures were reviewed and approved
by the Institutional Animal Care and Use Committee of
Shanghai University of TCM and carried out in adher-
ence to the ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research.
Chemicals
Celastrol was purchased from Sigma-Aldrich (USA), dis-
solved in DMSO, and administered to mice 30 min prior
to light exposure via intraperitoneal injection (i.p). Mice
unexposed to bright light and light-exposed mice with-
out celastrol treatment received DMSO injection only.
All-trans-retinal (atRAL) and lipopolysaccharides (LPS)
were obtained from Sigma-Aldrich (USA).
Cell culture
ARPE19 cells were purchased from the American
Type Culture Collection (ATCC) and cultured in
Dulbecco’s modified Eagle medium: Nutrient Mixture
F-12 (DMEM/F-12) (Gibco, Thermo Fisher Scientific,
USA) supplemented with 10 % fetal bovine serum,
50 μg/ml streptomycin, and 50 U/ml penicillin (Gibco,
Thermo Fisher Scientific, USA). RAW 264.7 cells were
obtained from Shanghai Institute of Biological Science
(SIBS) and grown in Dulbecco’s modified Eagle
medium (DMEM) (Gibco, Thermo Fisher Scientific,
USA) with 10 % fetal bovine serum, 50 μg/ml strepto-
mycin, and 50 U/ml penicillin (Gibco, Thermo Fisher
Scientific, USA).
LPS stimulation
After pretreatment with celastrol at indicated concentra-
tions for 30 min, ARPE19 or RAW 264.7 cells were
stimulated with LPS at concentrations of 1 μg/ml and
5 ng/ml, respectively. Cells were then harvested for RNA
extraction 6 h after LPS treatment.
In vitro detection of reactive oxygen species (ROS)
For in vitro ROS detection, ARPE19 cells were pre-
treated with celastrol at indicated concentrations for
30 min prior to incubation of atRAL at 20 μM. ROS
probe 2′,7′-dichlorofluorescein diacetate (DCF-DA)
(Sigma-Aldrich, USA) was then added to cells at 400 nM
and incubated at 37 °C for 10 min. ROS signal from
various treatments was obtained at the same setting
using IncuCyte ZOOM (ESSEN Bioscience, USA). Fluor-
escence quantification was performed with IncuCyte
ZOOM software using of the setting of green fluores-
cence integrated intensity. Relative fluorescence inten-
sities were calculated for statistical analyses.
Optical coherence tomography (OCT)
OCT (Optoprobe, Canada) was performed after anesthesia
of mice by pelltobarbitalum natricum, i.p, at the dose of
65 mg/kg bw. Pupils were dilated by 1 % tropicamide prior
to OCT imaging.
Histology and immunohistochemistry (IHC)
Eyes were enucleated, fixed in 4 % paraformaldehyde,
and processed for paraffin embedding. Paraffin sections
4 μm thick were subjected to hematoxylin and eosin
(H&E) staining and measurement of the thickness of
outer nuclear layer (ONL). For IHC, cryosections
12 um thick were incubated with primary antibodies
including mouse anti-Rhodopsin (1: 2000, Novusbio,
USA), rabbit anti-opsin M (1: 100, Millipore, USA),
goat anti-GFAP (1:200, Abcam, USA), rabbit anti-
vimentin (1:50, Cell Signaling Technology, USA),
rabbit anti-Iba1 (1:500, Wako, Japan), or rabbit anti-
COX2 (1:100, Abcam, USA), which was followed by
incubation of secondary antibodies including Cy3-
conjugated sheep anti-mouse, sheep anti-rabbit, or
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rabbit anti-goat secondary antibodies (1: 1000, Sigma-
Aldrich, USA). 4-6-Diamidino-2-phenylindole (DAPI)
staining was performed for nuclei visualization and
measurement of the thickness of outer nuclear layer
(ONL). Images were observed under fluorescent
microscope (DM6000B, Leica, Germany).
Electroretinogram (ERG)
Under dim red light, the dark-adapted mice were anes-
thetized with a mixture of ketamine hydrochloride
(82.5 mg/kg bw) and xylazine (8.25 mg/kg bw). Scotopic
ERGs were generated with flashes of green light at inten-
sities ranging from −2 log cd s m−2 to 3.1 log cd s m−2.
Five recordings were made at sufficient intervals be-
tween flash stimuli (from 5 s to 1 min) to allow recovery
from any photobleaching effects. ERG was recorded and
analyzed with the universal testing and electrophysio-
logical system, Ganzfeld (Phoenix Research labs, USA).
TdT-mediated dUTP nick-end labeling (TUNEL) assay
Cryosections 8 μm thick were used for TUNEL staining
following the manufacturer’s instructions (DeadEnd™
Fluorometric TUNEL system, Promega, USA). Images
were observed under fluorescent microscope (DM6000B,
Leica, Germany).
Real-time PCR analysis
Total RNA extraction of mouse retinas, ARPE 19, and
RAW 264.7 cells was performed using TRIzol reagent
(Invitrogen, USA). Reverse transcription was performed
using PrimeScript RT Master Mix (TaKaRa, Japan) and
real-time PCR was performed using QuantiTect SYBR
Green PCR Master Mix (Qiagen, USA) on Roche Light-
Cycler 480 II. All samples were run in triplicates; fold
changes of the expression of genes were calculated ac-
cording to 2−[Ct(target gene)−Ct(Gapdh)]. The primer se-
quences were listed in the Table 1.
In vivo detection of ROS
Dihydroethidium (DHE) (Sigma-Aldrich, USA) was ad-
ministered to the mice, i.p, at a dose of 20 mg/kg bw 2 h
prior to euthanization. Cryosections 12 μm thick were
subject to assessment of ROS signal under fluorescent
microscope (DM6000B, Leica, Germany).
Leukostasis assay
Intracardial perfusion was performed using 50 ml of 0.9 %
saline solution, followed by perfusion of fluorescein-
conjugated concanavalin A (ConA) (Vector Laboratories,
USA) at the dose of 6.25 mg/kg bw. After ConA perfusion,
unbound ConA was flushed out by perfusion with 50 ml of
0.9 % saline solution. Retinal flatmounts were examined
under fluorescent microscope (DM6000B, Leica, Germany).
Statistical analysis
All results were expressed as mean ± standard error of
mean (S.E.M.). Statistical analyses were performed using
independent-samples T test (SPSS 18, USA). Differences
were considered statistically significant if p values <0.05.
Results
Celastrol protected retinas against bright light-induced
photoreceptor degeneration
BALB/c mice were first exposed to bright light at the
intensity of 5000 lx for 2 h, and celastrol was adminis-
tered 30 min prior to light exposure at the dose of 1, 2.5,
and 5 mg/kg bw, respectively. OCT imaging was per-
formed 7 days after light exposure to evaluate retinal
Table 1 Primer sequences
Gene Forward primer Reverse primer
Mouse IL1β TGCCACCTTTTGACAGTGATG AAGGTCCACGGGAAAGACAC
Mouse Ccl2 AGCTGTAGTTTTTGTCACCAAGC GTGCTGAAGACCTTAGGGCA
Mouse COX2 CCGTACACATCATTTGAAGAACTTA CTACCATGGTCTCCCCAAAGAT
Mouse TNFα ACGTCGTAGCAAACCACCAA GCAGCCTTGTCCCTTGAAGA
Mouse ICAM-1 TCCGGACTTTCGATCTTCCAGCTAC CCAGGTATATCCGAGCTTCAGAGGC
Mouse VCAM-1 AAGAAAGGGAGACTGTCAAAGAACT AACTTCATTATCTAACTTCCTGCCC
Mouse VEGF GTACTTGCAGATGTGACAAGCCA GGTGACATGGTTAATCGGTCTTT
Mouse GAPDH CCGGTGCTGAGTATGTCGT CCTTTTGGCTCCACCCTTC
Human IL1β TTATTACAGTGGCAATGAGGATGAC GGAAGGAGCACTTCATCTGTTTAG
Human Ccl2 CTCATAGCAGCCACCTTCATTC CTCTGCACTGAGATCTTCCTATTG
Human COX2 GATTTGACCAGTATAAGTGCGATTG GTTTGGAGTGGGTTTCAGAAATAAT
Human TNFα CCTCTCTCTAATCAGCCCTCTG CTACAACATGGGCTACAGGCTT
Human ICAM-1 AAGATAGCCAACCAATGTGCTAT AAGATAGCCAACCAATGTGCTAT
Human GAPDH ACTCTGGTAAAGTGGATATTGTTGC GGAATCATATTGGAACATGTAAACC
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structures. As shown in Additional file 1: Figure S1a,
compared to that from the mice unexposed to bright
light, severely disrupted photoreceptor structure was ob-
served in light-exposed DMSO-treated mice, which was
primarily characterized by diminished ONL in the retina.
In contrast, dose-dependent preservation of ONL was
observed in celastrol-treated mice. Partial retinal protec-
tion could be observed when celastrol was administered
at the dose of 2.5 mg/kg bw and improved protection
was observed when celastrol was given at 5 mg/kg bw.
Similar protection of celastrol treatment was observed
when BALB/c mice were exposed to light at 10,000 lx
for 30 min (Additional file 1: Figure S1b). To further
evaluate the retinal protection of celastrol, light exposure
was delivered at 10,000 lx for 2 h. As shown in
Additional file 1: Figure S1c, no protection was observed
when celastrol was administered at the dose of 1 and
2.5 mg/kg bw, respectively; however, remarkable protec-
tion was observed in the mice that received celastrol at
the dose of 5 mg/kg bw.
Histological examination of retinal gross histology and
quantification of photoreceptor changes were further
performed. Compared to that from the mice unex-
posed to bright light, prominent retinal morphological
disruption was observed in DMSO-treated mice ex-
posed to light at 5000 lx for 2 h (Additional file 1:
Figure S2a and c), 10,000 lx for 30 min (Additional file
1: Figure S2b and d), or 10,000 lx for 2 h (Fig. 1a, b),
which was characterized by disrupted and diminished
photoreceptor outer segment (OS) and inner segments
(IS) and reduced thickness of the ONL. In distinct
contrast, when light was applied at 5000 lx for 2 h
(Additional file 1: Figure S2a and c) or 10,000 lx for
30 min (Additional file 1: Figure S2b and d), partial
protection from the loss of ONL was observed in the
mice that were treated by celastrol at the dose of
2.5 mg/kg bw and an improved protection was ob-
served in the mice treated by celastrol at the dose of
5 mg/kg bw. When light were applied at 10,000 lx for
2 h, significant retinal protection was observed in
Fig. 1 Celastrol preserved photoreceptor morphology in light-exposed BALB/c mice. Dark-adapted BALB/c mice were exposed to light at the intensity of
10,000 lx for 2 h after pretreatment with either vehicle control (DMSO) or celastrol at 1 mg/kg bw (celastrol 1), 2.5 mg/kg bw (celastrol 2.5), and 5 mg/kg bw
(celastrol 5). a Eyes were enucleated 7 days after light exposure, and paraffin sections were made and stained with H&E for retinal histological examination
using light microscopy. b ONL thickness was quantified at 500 μm off optical nerve head in both superior and inferior retina. c Dark-adapted BALB/c mice
were exposed to light at the intensity of 10,000 lx for 2 h after pretreatment with either DMSO or celastrol at 5 mg/kg bw. IHC examination of rhodopsin
(Rho) and opsin M (in red) expression in the central retinas (1000 μm off ONH) were performed 7 days after light exposure along with DAPI counterstaining
(in blue) in the cryosections. d The thickness of ONL was measured in DAPI-stained cryosections. Asterisk indicates disorganized and reduced length of
outer/inner segments and diminished ONL. ONH optic nerve head, ONL outer nuclear layer, INL inner nuclear layer. Scale bar: 50 μm. Data were expressed
as mean ± S.E.M. (n= 4–6 per group). *Compared to that from no light, p< 0.05; #compared to that from DMSO, p< 0.05
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mice that were treated by celastrol at 5 mg/kg bw
(Fig. 1a, b).
Retinal expression of rhodopsin (Rho) and mid-
wavelength sensitive cone opsin (opsin M) was also
examined. As shown in Fig. 1c and Additional file 1:
Figure S3, compared to the abundant expression pattern
of Rho and opsin M throughout the retinas from the
mice unexposed to bright light, residual expression of
these photoreceptor markers was observed in central
retinas but not peripheral retinas of DMSO-treated mice
exposed to light at 10,000 lx for 2 h. In contrast, well-
organized and abundant expression of Rho and opsin M
was readily observed in central retinas of light-exposed
mice treated by celastrol at 5 mg/kg bw. Quantification
of ONL thickness after DAPI staining showed that sig-
nificant reduction in the thickness of ONL from light-
exposed DMSO-treated mice compared to that from the
mice unexposed to bright light, whereas the ONL thick-
ness was significantly preserved in the retinas from
light-exposed celastrol-treated mice (Fig. 1d). These re-
sults collectively indicated significant morphological pro-
tection of celastrol against light-induced photoreceptor
degeneration in BALB/c mice.
Celastrol protected retinas against bright light-induced
functional impairment in BALB/c mice
ERG was further performed to evaluate the retinal func-
tion. As shown in Fig. 2a, compared to that from the
mice unexposed to bright light, significant reduction in
scotopic a-wave and b-wave amplitudes was observed
in DMSO-treated mice exposed to bright light at
10,000 lx for 30 min. However, significantly increased
scotopic a-wave and b-wave amplitudes were observed
in light-exposed mice treated by celastrol at 5 mg/kg
Fig. 2 Celastrol preserved retinal function and protected against photoreceptor apoptosis in light-exposed BALB/c mice. a Dark-adapted BALB/c
mice were exposed to light at the intensity of 10,000 lx for 30 min after pretreatment with DMSO and celastrol at 5 mg/kg bw. Retinal function
was examined by ERG 4 days after light exposure. Scotopic ERG was recorded and both a-waves and b-waves were plotted to evaluate retinal
function. Data were expressed as mean ± S.E.M. (n = 4 per group). *Compared to that from no light, p < 0.05; #compared to DMSO, p < 0.05. b
Dark-adapted BALB/c mice were exposed to light at 10,000 lx for 2 h after pretreatment with either DMSO or celastrol. Cryosections were made
from eye cups collected from mice 3 h, 1 day, 3 days, and 7 days after light exposure along with those from the mice without light exposure
(no light). Apoptosis was then examined by TUNEL staining (in green) and DAPI counterstaining (in blue) (n = 3–5 per group). ONL outer nuclear
layer, INL inner nuclear layer. Scale bar: 50 μm
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bw compared to that from DMSO-treated mice. These
results supported functional protection of retinas
against bright light-induced degeneration as a result of
celastrol treatment.
Celastrol attenuated light-induced photoreceptor
apoptosis
To further characterize the retinal protective effect of
celastrol, apoptosis was examined by TUNEL assay at
different time points after bright light exposure. As
shown in Fig. 2b, no TUNEL-positive cells were found
in the retinas from the mice unexposed to bright light.
A few TUNEL-positive cells were detected in the ONL
of retinas from DMSO-treated mice 3 h after bright light
exposure at 10,000 lx for 2 h and TUNEL positivity
peaked at 3 days after light exposure prior to massive
clearance of photoreceptor cells by 7 days. At 7 days
post light exposure, the remaining photoreceptor cells in
the retinas were predominantly TUNEL positive. In dis-
tinct contrast, retinas from mice treated by celastrol at
5 mg/kg bw were characterized by remarkably decreased
number of TUNEL-positive cells in the ONL. These
results indicated that celastrol treatment protected
photoreceptor cells from light-induced apoptosis.
Celastrol alleviated light-induced oxidative stress in the
retinas
Retinal oxidative stress was further evaluated by examin-
ing in situ ROS production. As shown in Additional file
1: Figure S4, no visible ROS signal was detected in the
retinas from the mice unexposed to bright light. In con-
trast, ROS production was remarkably increased in the
retinal pigment epithelium (RPE) from DMSO-treated
mice exposed to light at 10,000 lx for 2 h. The increase
in ROS production in RPE was observed at 3 and 6 h
after light exposure and persistent until 7 days after light
exposure. It was also noted that the ROS signal was
most prominent in the RPE 1 day after light exposure
and in the meantime, ROS signals was detectable in the
ONL in light-exposed DMSO-treated mice. Therefore,
retinal ROS production was examined in light-exposed
celastrol-treated mice 1 day after bright light exposure.
As shown in Fig. 3a, remarkably decreased ROS signal in
the RPE was observed in light-exposed celastrol-treated
mice 1 day after light exposure. Moreover, ROS signal
was not detected in the ONL from light-exposed
celastrol-treated mice (Fig. 3a). The retinal expression of
heme oxygenase 1 (HO-1) whose induced expression is
indicative of light-induced oxidative stress in the retina
Fig. 3 Celastrol suppressed retinal oxidative stress in light-exposed BALB/c mice. a Dark-adapted BALB/c mice were exposed to light at 10,000 lx for
2 h after pretreatment with either DMSO or celastrol at 5 mg/kg bw. Retinal ROS production was examined by DHE probe 1 day after light exposure in
light-exposed mice and the mice without light exposure (no light). DAPI staining (in blue) and ROS signals (in red) were examined and recorded by
fluorescence microscope (n = 4 per group). RPE retinal pigment epithelium, ONL outer nuclear layer, INL inner nuclear layer. Scale bar: 50 μm. b Retinas
were collected 6 h and 1 day after light exposure and real-time PCR analyses of the expression of HO-1 was performed. Relative fold change against
that from the mice without light exposure (no light) was presented. Data were expressed as mean ± S.E.M. (n = 4–6 per group). *Compared to that from
no light, p < 0.05; #compared to that from DMSO, p < 0.05
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[22] was also analyzed. As shown in Fig. 3b, compared
to that from the mice unexposed to bright light, signifi-
cantly increased expression of HO-1 was observed in the
retinas of light-exposed DMSO-treated mice both 6 h
and 1 day after bright light exposure. Celastrol treatment
resulted in significantly reduced expression of HO-1
both at 6 h and 1 day after light exposure. These results
demonstrated that celastrol protected retinas against
light-induced oxidative stress.
Celastrol attenuated light-induced expression of
proinflammatory genes in the retina
The retinal expression of proinflammatory and chemo-
tactic cytokines was further examined, which included
interleukin 1β (IL1β) [23], chemokine (C-C motif ) ligand
2 (Ccl2) [24], cyclooxygenase-2 (COX2) [25], and TNFα
[26]. As shown in Fig. 4, compared to that from the mice
unexposed to bright light, bright light exposure at
10,000 lx for 2 h resulted in significantly increased
expression of IL1β, Ccl2, and COX2 at 6 h and 1 day
after light exposure in DMSO-treated mice. Increased
expression of TNFα was not observed at 6 h but seen
1 day after light exposure. In contrast, compared to
that from light-exposed DMSO-treated mice, signifi-
cantly decreased expression of IL1β, Ccl2, COX2, and
TNF-α was observed in the retinas from light-exposed
celastrol-treated mice. IHC examination of retinal ex-
pression of COX2 was then performed. As shown in
Fig. 5, expression of COX2 was observed in the GC,
inner plexiform layer (IPL), and inner nuclear layer
(INL) in the mice unexposed to bright light. In the ret-
inas from light-exposed DMSO-treated mice, the
immunoreactivity of COX2 was also detected in the
ONL 1 day after light exposure at 10,000 lx for 2 h,
which was not observed in the retinas from light-
exposed celastrol-treated mice. These results provided
evidence supporting that celastrol alleviated light-
induced retinal inflammation.
Celastrol inhibited leukostasis in the retinal vasculatures
in bright light-exposed mice
Leukostasis is a pathological event closely associated with
tissue inflammation [27]. Increased expression of proin-
flammatory genes in light-exposed retinas prompted us to
further examine whether leukostasis is associated with
light-induced retinal degeneration. Fluorescein-ConA la-
beling of adherent leukocytes in the retinal vasculature
was examined after light exposure at 10,000 lx for 2 h.
Adherent leukocytes were occasionally encountered in the
retinal vasculatures from the mice unexposed to bright
light; however, loci of adherent leukocytes were frequently
observed in the retinal vasculature in light-exposed
DMSO-treated mice 3 h after light exposure (Additional
file 1: Figure S5). Much less adherent leukocytes were ob-
served at 1 and 3 days after light exposure (Additional file
1: Figure S5). The effect of celastrol treatment on light-
Fig. 4 Celastrol attenuated the expression of proinflammatory genes in light-exposed retinas. Dark-adapted BALB/c mice were exposed to bright light at
10,000 lx for 2 h after pretreatment with either DMSO or celastrol at 5 mg/kg bw. Retinas were collected 6 h and 1 day after light exposure and further
processed for total RNA isolation, reverse transcription, and real-time PCR analyses for expression of IL1β, Ccl2, COX2, and TNFα, respectively.
After normalizing the expression to GAPDH, relative fold change of expression was calculated against that from the retinas collected from
the mice unexposed to bright light (no light). Data were expressed as mean ± S.E.M. (n = 4–6 per group). *Compared to that from no
light, p < 0.05; #compared to that from DMSO, p < 0.05
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induced leukostasis was therefore assessed 3 h after light
exposure. As shown in Fig. 6a, b, significantly decreased
number of leukostasis loci in retinal vasculature was ob-
served in light-exposed celastrol-treated mice compared
to that from light-exposed DMSO-treated mice.
Leukostasis is mediated by intercellular adhesion
molecule-1 (ICAM-1) [28], vascular adhesion molecule-
1 (VCAM) [29], and vascular endothelial growth factor
(VEGF) [30]. The expression of ICAM-1, vascular adhe-
sion molecule-1 (VCAM-1), and VEGF was thus exam-
ined in the retinas. As shown in Fig. 6c, compared to
that from the mice unexposed to bright light, transient
and robust upregulation of retinal ICAM-1 expression
was observed 6 h after light exposure in DMSO-treated
mice. Retinal VCAM-1 expression exhibited increased
expression at 6 h and 1 day after light exposure. Signifi-
cant increase in retinal VEGF expression was observed
at 6 h but not at 1 day after light exposure. In contrast,
significantly decreased expression of ICAM-1 and
VCAM-1 was observed in the retinas from light-exposed
celastrol-treated mice at both 6 h and 1 day after light
exposure. No significant difference in the retinal expres-
sion of VEGF was observed as a result of celastrol treat-
ment in light-exposed mice. These results demonstrated
that leukostasis was an early event associated with light-
induced retinal degeneration, which could be signifi-
cantly attenuated by celastrol treatment.
Celastrol suppressed microglial activation and reactive
gliosis in the retina in bright light-exposed mice
Microglial activation indicates sensing of retinal insults
by microglia and contributes to tissue inflammation
given the immunogenic nature of resident microglia,
which could be identified by ectopic expression of
microglial marker Iba-1. Moreover, gliosis reflects non-
specific changes in Müller glial cells in response to even
subtle tissue damage, which is characterized by upregu-
lated expression of intermediate filament protein glial
fibrillary acid protein (GFAP) and vimentin. Thus, the
effect of celastrol on expression of Iba-1, GFAP, and
vimentin was further examined. As shown in Fig. 7a,
compared to ramified expression restricted to the OPL
of retinas in the mice without bright light exposure, en-
larged amoeboid-shaped Iba-1-positive microglia were
readily detected in INL, ONL, and subretinal spaces of
retinas 3 days after bright light exposure in DMSO-
treated mice. At 7 days after bright exposure, ONL was
nearly diminished and ectopic expression of Iba-1 was
not readily detected in light-exposed DMSO-treated
mice (Additional file 1: Figure S6). In contrast, Iba-1
immunopositivity was evidently attenuated in the ONL
and INL of celastrol-treated mice 3 days after bright ex-
posure (Fig. 7a) and was not detected in the ONL of
celastrol-treated mice 7 days after bright light exposure
(Additional file 1: Figure S6). Moreover, as shown in
Fig. 7b, the immunoreactivity of GFAP was prominently
detected in the nerve fiber layer (NFL) in the retina of
the mice unexposed to bright light. However, immunore-
activity of GFAP was readily observed in IPL, INL, and
remaining ONL in the retina from DMSO-treated mice
7 days after light exposure at 10,000 lx for 2 h. Similar
expression pattern was observed for the expression of
vimentin, which became prominent throughout the
damaged retina. In contrast, ectopic expression of GFAP
and vimentin was not observed in the retina from light-
exposed celastrol-treated mice (Fig. 7c). These results
Fig. 5 Celastrol suppressed light-induced expression of COX2 in photoreceptors. Dark-adapted BALB/c mice were exposed to light at 10,000 lx
for 2 h after pretreatment with either DMSO or celastrol at 5 mg/kg bw. Eyes cups were made from enucleated eyes collected 1 and 7 days after
light exposure. Cryosections were subject to IHC examination of COX2 expression (in red) and counterstained by DAPI (in blue) (n = 3–5 per
group). ONL outer nuclear layer, INL inner nuclear layer. Scale bar: 50 μm
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indicated celastrol treatment results in suppressed ret-
inal microglial activation and gliosis in bright light-
exposed BALB/c mice.
Celastrol attenuated oxidative stress and suppressed the
expression of proinflammatory genes in vitro
To better characterize the pharmacological activities of
celastrol, two cellular models were adopted. Firstly,
ARPE19 cells, immortalized human RPE cells, were
subjected to atRAL incubation to mimic light-induced
retinal damage and oxidative stress in vivo [31]. ROS
production in ARPE19 cells was then examined in the
absence or presence of celastrol treatment. As shown in
Fig. 8a, b, compared to that from vehicle controls,
atRAL induced significant increase in ROS production,
whereas significantly reduced ROS production was ob-
served by celastrol treatment. Secondly, LPS-induced
expression of proinflammatory genes was assessed in
ARPE19 cells and mouse macrophage RAW264.7 cells
in the presence of vehicle or celastrol treatment.
Fig. 6 Celastrol suppressed retinal leukostasis and retinal expression of ICAM-1 and VCAM-1 in light-exposed mice. Dark-adapted BALB/c mice
were exposed to bright light at 10,000 lx for 2 h after pretreatment with either DMSO or celastrol at 5 mg/kg bw. a Fluorescein-conjugated ConA
labeling for adherent leukocytes in retinal vasculature was examined in mice without bright light exposure (no light) and 3 h after light exposure.
Retinal flatmounts were made and observed under fluorescent microscope. b The number of loci with adherent leukocytes per field in each
retina was counted (9–14 fields per retina, n = 4–6 retinas per group). Scale bar: 100 μm. c Retinas were collected 6 h and 1 day after light exposure
and subjected to real-time PCR analyses for expression of ICAM-1, VCAM-1, and VEGF, respectively. Relative fold change against that from the mice
without bright light exposure (no light) was presented. Data were expressed as mean ± S.E.M. (n = 4–6 per group). *Compared to that from no light,
p < 0.05; # compared to that from DMSO, p < 0.05
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Celastrol treatment resulted in significant suppression of
LPS-induced expression of IL1β and Ccl2 in both
APRE19 cells (Fig. 9a) and RAW264.7 cells (Fig. 9b).
Additionally, although no endogenous expression and
overt LPS-stimulated induction of TNFα and ICAM-1
was observed in ARPE19 cells, celastrol treatment sig-
nificantly suppressed LPS-induced expression of TNFα
and ICAM-1 in RAW264.7 cells (Fig. 9b). These results
together not only confirmed the anti-inflammatory effect
of celastrol in immune cells [18, 32] but also implied dir-
ect antioxidant and anti-inflammatory effects of celastrol
in RPE cells.
Discussion
The current study revealed that celastrol protected the
retinas from morphological and functional impairment
in bright light-exposed BALB/c mice. The retinal protec-
tion of celastrol was accompanied by remarkable sup-
pression of light-induced photoreceptor apoptosis, ROS
overproduction in RPE and photoreceptor cells, retinal
expression of proinflammatory factors, leukostasis, ret-
inal microglial activation, and gliosis.
Light-induced oxidative stress in the retina is causally
associated with the pathogenesis of retinal degenerative
disorders in patients and animal models [4, 33, 34].
Accumulated evidence supports an essential role for
oxidative stress in RPE dysfunction that is primarily im-
plicated in the pathogenesis of AMD. Oxidative damage
to RPE is an early event in the development of AMD,
and RPE dysfunction contributes to the loss of photore-
ceptors during the progression of AMD [35, 36]. The
current study revealed rapidly occurring oxidative stress
Fig. 7 Celastrol suppressed microglial activation and gliosis in the retinas of bright light-exposed BALB/c mice. Dark-adapted BALB/c mice were
exposed to bright light at 10,000 lx for 2 h after pretreatment with either DMSO or celastrol at 5 mg/kg bw. Cryosections made from eye cups
collected 3 days after light exposure were subjected to IHC examination for the expression of Iba-1 (in red) (n = 3–5 per group) (a). Cryosections made
from eye cups collected 7 days after light exposure were subjected to IHC examination of GFAP (in red) (n = 3–5 per group) (b) and vimentin (in red)
(c) (n = 3–5 per group). DAPI counterstaining (in blue) was performed to visualize retinal gross morphology. ONL outer nuclear layer, INL inner nuclear
layer. Scale bar: 50 μm
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in RPE in bright light-exposed BALB/c mice. It is also
noteworthy that oxidative stress in RPE was found to be
more prominent and persistent than that detected in
photoreceptor. The oxidative stress in RPE was readily
detected 3 h after bright light exposure when only a few
apoptotic photoreceptor cells were observed (Additional
file 1: Figure S4 and Fig. 2). Prominent RPE oxidative
stress was concomitant with increased photoreceptor
cell death seen at 1 day after bright light exposure but
was prior to massive photoreceptor cell death detected
at 3 days after bright exposure (Additional file 1: Figure
S4 and Fig. 2), providing in vivo evidence supporting
that RPE oxidative stress is likely implicated in photo-
receptor cell death. Most importantly, a remarkable
effect of celastrol on suppressing light-induced oxidative
stress in RPE was demonstrated (Fig. 3). Moreover,
reduced level of ROS was observed in atRAL-stimulated
ARPE 19 cells as a result of celastrol treatment, suggest-
ing a direct effect of celastrol on attenuating oxidative
stress in RPE cells (Fig. 8). These results partially
explained the protective effects of celastrol against
photoreceptor degeneration, and more importantly, they
provided a potential pharmacological solution to alleviat-
ing oxidative stress in RPE.
Oxidative stress is noted as a principal mechanism of
tissue stress, triggering inflammatory response in the ret-
ina [37–39]. The crosstalk between oxidative stress and
inflammation is witnessed at molecular level as well. For
instance, during retinal inflammation, oxidative stress is
required for CCL2 production in response to inflamma-
tory stimuli, which plays critical roles in promoting
inflammation response by recruiting and activating
Fig. 8 Celastrol reduced atRAL-induced oxidative stress in APRE19 cells. ARPE19 cells were pretreated with celastrol at indicated concentrations
for 30 min prior to incubation of atRAL at 20 μM for 6 h. DCF-DA was then added to cells at 400 nM and incubated at 37 °C for 10 min. Cells was
imaged for fluorescent signal indicative of ROS production under the same exposure setting using IncuCyte ZOOM (a). Fluorescence quantification was
performed by IncuCyte ZOOM software under the setting of green fluorescence integrated intensity. Relative fluorescence intensities were calculated for
statistical analyses (b). Data were expressed as mean ± S.E.M. (n= 4 per group). Scale bar: 150 μm. *Compared to that from vehicle-treated cells without
atRAL and celastrol incubation, p< 0.05; #compared to that from atRAL-stimulated vehicle-treated cells, p< 0.05
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various immune cells including monocytes, macro-
phages, and lymphocytes [40]. Celastrol treatment not
only resulted in strong inhibition of light-induced oxida-
tive stress in RPE but also significantly suppressed ret-
inal expression of proinflammatory genes including Ccl2
in vivo. Moreover, activation of resident microglia plays
important role in modulating inflammatory responses
during the course of neurodegeneration. Activated
microglia promotes neurodegeneration by secreting pro-
inflammatory factors such as IL1β and TNFα [41, 42]. In
human, retinal microglial activation is noted to be an
event associated with photoreceptor death in several
forms of retinal degenerative disorders [43]. Activated
microglia has been increasingly recognized as hallmark
pathology in degenerative retinas and contributes signifi-
cantly to photoreceptor loss in mouse models manifest-
ing light-induced retinal degeneration [11, 44, 45].
Moreover, therapies with inhibitory effects on microglial
activation have been demonstrated to be neuroprotective
in light-challenged retinas, emerging as new beneficial
concepts for tackling related retinal degenerative disor-
ders. For instance, it has been revealed that minocycline
suppresses microglial activity in cultured microglial cells,
attenuates microglial activation in the retinas, and pro-
tects against bright light-induced retinal degeneration in
vivo [44]. Translocator protein (18 kDa) is highly
expressed in reactive retinal microglia [46, 47], and a
recent study has shown that it can be successfully tar-
geted to counteract microglial activation and bright
light-induced mouse retinal degeneration [45]. Inhibition
of microglial activation is also protective against light-
induced retinal damage in rats [48]. Of interest, it has
been demonstrated that celastrol is equipped with direct
suppressive effect on microglia activity in vitro. For
example, it has been shown that in cultured mouse
microglial BV-2 cells, celastrol inhibits LPS-induced up-
regulation of proinflammatory factors such as IL1β and
TNFα [49]. Celastrol also suppresses double-strand
RNA-stimulated microglial activation in mouse micro-
glial MG-6 cells [50]. Here, we further showed that
celastrol treatment suppressed bright light-induced ret-
inal microglial activation in vivo (Fig. 7a). Given the
neurotoxic nature of activated microglia, we reason that
a direct suppressive activity of celastrol on microglial
Fig. 9 Celastrol suppressed the expression of proinflammatory genes in LPS-stimulated ARPE19 and RAW264.7 cells. ARPE19 (a) or RAW264.7 cells
(b) were pretreated with celastrol at indicated concentrations for 30 min, which was followed by LPS incubation at concentrations of 1 μg/ml
and 5 ng/ml, respectively. Cells were harvested 6 h later for RNA extraction. Real-time PCR analyses were subsequently performed to examine the
expression of IL1β, Ccl2, TNFα, and ICAM-1. Data were expressed as mean ± S.E.M. (n = 4 per group). *Compared to that from vehicle-treated cells
without LPS and celastrol incubation, p < 0.05; #compared to that from the vehicle-treated cells stimulated with LPS, p < 0.05
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activation could contribute significantly to its protective
effects against bright light-induced retinal degeneration.
Additionally, LPS-stimulated proinflammatory gene
expression was significantly suppressed by celastrol
treatment in ARPE19 and RAW264.7 cells (Fig. 9).
However, LPS-induced TNFα expression was not ob-
served in ARPE19 cells as that in RAW264.7 cells
(Fig. 9b). These findings suggest that although both
RPE and immune cells are likely the cellular targets of
the anti-inflammatory actions of celastrol, they may
play differential part in promoting inflammatory re-
sponse under stress conditions.
Leucocytes play a crucial role in inflammation by
interacting with endothelial cells, migrating to the sites
of inflammation and releasing inflammatory cytokines.
Under inflammatory conditions, endothelial cells are
activated and express adhesion molecules including
VEGF, ICAM-1, and VCAM-1 that cause leukocyte-
endothelial cell interactions [51]. ICAM-1-mediated
leukostasis has been identified as an early pathological
event in the mouse model of diabetic retinopathy
[52, 53]. Significantly enhanced expression of ICAM-
1, VCAM-1, and VEGF in light-exposed retinas to-
gether with leukostasis in the retinal vasculature
(Fig. 6 and Additional file 1: Figure S5) were ob-
served prior to massive photoreceptor death (Fig. 2b),
providing additional evidence supporting the notion
that inflammation is associated with photoreceptor
degeneration. However, future studies are required to
delineate the link between leukostasis and photorecep-
tor death. Nonetheless, celastrol was shown here to
significantly suppress the expression of ICAM-1 and
VCAM-1 and decrease leukostasis lesions in retinal
vasculature in bright light-exposed mice. These results
may reinforce the concept of anti-inflammation in
developing photoreceptor protective therapies. More-
over, LPS-induced ICAM-1 expression was not ob-
served in APRE19 cells as that seen in RAW264.7 cells
(Fig. 9b), and celastrol significantly suppressed LPS-
induced ICAM-1 expression in RAW264.7 cells,
further suggesting differential contributions of RPE
and immune cells in inflammatory responses and the
anti-inflammatory activity of celastrol.
Lastly, it is also noted celastrol does not have as
significant an impact on steady-state retinal gene ex-
pression in the mice without bright light exposure
(Additional file 1: Figure S7) as that in the mice ex-
posed to bright light (Figs. 3b, 4 and 6c). Among eight
genes analyzed, a marginal decrease of less than 30 %
in the expression of VCAM-1 was observed 6 h but
not 24 h after celastrol administration. A similar mar-
ginal decrease in VEGF expression was observed 24 h
after celastrol administration. An about 1.9-fold in-
crease in Ccl2 was observed in the retinas 6 h after
celastrol administration. The rest of genes exhibited
no significant changes.
Conclusions
In summary, we have identified for the first time a po-
tent effect of celastrol in protecting against light-induced
massive loss of photoreceptors. The current findings also
provide additional evidence supporting that oxidative
stress in RPE and early activation of inflammatory re-
sponse are implicated in the pathogenesis of light-
induced photoreceptor degeneration, which can be sig-
nificantly attenuated by celastrol administration. These
findings thus support further evaluation of celastrol as a
pharmacological candidate treating related retinal degen-
erative disorders.
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